The company maintained a competitive ARPOB while steadily improving occupancy, driven by higher patient volumes and efficient capacity utilization
The facility is dedicated to breakthrough innovations in laboratory instruments that detect infectious diseases, cancer, and blood disorders
A PRV is a tradable voucher granted by the FDA to encourage the development of new treatments for rare pediatric diseases
Glucon-D maintained its leadership position with a 59% MAT market share
Nine-month revenue grew 17.5% to Rs 76,277 lakh, EBITDA climbed to Rs 15,981 lakh, and net profit reached Rs 8,200 lakh
The Poultry Healthcare Division delivered a strong performance, posting 32% revenue growth in Q3 FY26 and 17% growth over the nine-month period
The company recorded consolidated revenue of Rs. 660 crore in Q3 FY26, up
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
rofitability showed strong momentum, with EBITDA rising 44.9% YoY to Rs. 8,697 million
On a proforma basis in Q3 FY26, revenues grew by 15% YoY to Rs. 2,366 Cr and operating EBITDA increased by 22% YoY to Rs. 503 Cr
Subscribe To Our Newsletter & Stay Updated
